Regeneron Pharmaceuticals
Latest statistics and disclosures from Regeneron Pharmaceuticals's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ALNY, NTLA, ADVM, ACET, and represent 100.00% of Regeneron Pharmaceuticals's stock portfolio.
- Reduced shares in these 1 stock: ALNY (-$1.4B).
- Regeneron Pharmaceuticals was a net seller of stock by $-1.4B.
- Regeneron Pharmaceuticals has $700M in assets under management (AUM), dropping by -52.83%.
- Central Index Key (CIK): 0000872589
Tip: Access up to 7 years of quarterly data
Positions held by Regeneron Pharmaceuticals consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Regeneron Pharmaceuticals
Regeneron Pharmaceuticals holds 4 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Common Stock (ALNY) | 90.6 | $635M | -68% | 1.4M | 456.00 |
|
| Intellia Therapeutics Common Stock (NTLA) | 9.1 | $64M | 3.7M | 17.27 |
|
|
| Adverum Biotechnologies Common Stock (ADVM) | 0.1 | $820k | 181k | 4.53 |
|
|
| Adicet Bio Common Stock (ACET) | 0.1 | $784k | 968k | 0.81 |
|
Past Filings by Regeneron Pharmaceuticals
SEC 13F filings are viewable for Regeneron Pharmaceuticals going back to 2024
- Regeneron Pharmaceuticals 2025 Q3 filed Nov. 7, 2025
- Regeneron Pharmaceuticals 2025 Q2 filed Aug. 1, 2025
- Regeneron Pharmaceuticals 2025 Q1 filed May 2, 2025
- Regeneron Pharmaceuticals 2024 Q4 filed Feb. 7, 2025